AstraZeneca stock weighs Q2 growth against trial setback

Published on 09/28/2026 at 15:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca stock carried 6.40 percent Q2 revenue growth into September 28, 2026, with core EPS at USD 2.63. Deutsche Bank lifted its target to GBp 11,700.

Wissenschaftler im weißen Kittel arbeiten in modernem Pharma-Forschungslabor — AstraZeneca plc (ISIN GB0009895292) betreibt moderne Forschungslabore für pharmazeutische Wirkstoffentwicklung und klinische Studien weltweit, Illustration mit AI erstellt.

AstraZeneca stock was trading at GBp 12,542.00 on the London Stock Exchange at 2:10 p.m. BST on September 28, 2026, down GBp 10.00, or 0.08 percent, from the previous close. The immediate picture combines a 6.40 percent year-over-year revenue increase in Q2 2026 with a clinical setback that has reshaped parts of the oncology debate.

Q2 growth reaches USD 15.38 billion

According to MarketBeat on September 17, 2026, AstraZeneca reported Q2 adjusted core EPS of USD 2.63, ahead of the USD 2.50 consensus estimate. Revenue reached USD 15.38 billion against USD 15.44 billion expected, while the year-over-year comparison showed 6.40 percent growth.

Yahoo Finance reported on September 9, 2026, that Oncology revenue grew 18.00 percent in the first half to USD 14.12 billion, while Rare Disease revenue increased 13.00 percent. The figures give investors a more specific growth mix than the group total alone.

Analysts reset the risk balance

The counterweight is clinical execution. MarketBeat identified the Phase III SERENA-4 failure for breast-cancer drug camizestrant as a key pressure on the oncology pipeline. That event helps explain why rating changes have focused on risk and valuation despite the Q2 earnings beat.

According to Sharecast on September 15, 2026, Deutsche Bank upgraded AstraZeneca from Sell to Hold and raised its price target from GBp 11,500.00 to GBp 11,700.00. The bank linked the change to a revised risk-reward view after the SERENA-4 result and recent underperformance against European large-cap peers.

Stock remains below its yearly high

AstraZeneca stock was 20.29 percent below its 52-week high of GBp 15,732.00 and above its 52-week low of GBp 9,892.00 on September 28, 2026. Trading volume stood at 534,224 shares, making the intraday move modest relative to the broader price range.

TradingView lists October 30, 2026, as the next earnings release date for Q3 2026. That report should put the 6.40 percent Q2 revenue growth and the pipeline concerns into the same updated operating frame.

GBp 12,542.00 at the LSE

AstraZeneca stock was last at GBp 12,542.00 on the LSE at 2:10 p.m. BST on September 28, 2026, with a daily change of -0.08 percent. The price, operating figures and analyst revisions leave the next earnings report as the clearest dated checkpoint.